Jun 10, 2024, 07:25
The phase III NETTER-2 trial published in The Lancet and presented by Pamela Kunz at ASCO24 – Yale Cancer Center
Yale Cancer Center shared a post on X:
“The phase III NETTER-2 trial published in The Lancet and presented by Pamela Kunz at ASCO24 showed Lu-Dotatate should be considered a new standard of care in 1st line therapy for pts with grade 2 or 3 advanced gastroenteropancreatic neuroendocrinetumors.”
Additional information.
Source: Yale Cancer Center/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12